Under Bourla’s leadership, Pfizer was the first to win FDA approval of an mRNA vaccine against Covid-19 in late 2020, along with its partner BioNTech, followed a year later by authorization for the oral Covid antiviral Paxlovid. Then, last August, Pfizer — simultaneously with Moderna — got the FDA’s nod last for a revamped vaccine that also targets the Omicron variant. And though overall vaccine sales dipped last year, Bourla predicts a bright future for Pfizer, with 19 drug and vaccine launches planned between January 2023 and June 2024. Those include a vaccine for respiratory syncytial virus and treatments for multiple myeloma and alopecia. “It’s a very exciting pipeline that will make big differences in people’s lives,” Bourla said at a STAT event last fall. This is the second year in a row in which Bourla has appeared on the STATUS List.
Industry
Location
-
New York, NY
